Thomas Kjærsgaard Jørgensen

Thomas Kjærsgaard Jørgensen has worked in the biotechnology and pharmaceutical industry since 1993. Thomas Kjærsgaard began their career at Novo Nordisk as a Research Scientist, Analysis Development and Project Coordination. In 1999, they joined AstraZeneca R&D as a Group Leader, Protein Purification and Characterization, where they were responsible for setting project teams and hiring personnel. In 2002, they moved to Maxygen ApS as an Associate Director, Purification, Formulation and Characterization (CMC). From 2008 to 2018, they were a Project Director and Alliance Director at Symphogen A/S, where they were the director of the Sym004 oncology project and managed three biologics projects within oncology and infectious disease. From 2013 to 2016, they were the Director of the Microbiome Center at Chr. Hansen A/S. From 2018 to 2022, they were the Senior Director at Savara Inc., where they were the Project Lead and CMC Project Leader for two projects. Currently, they are the Chief Executive Officer at Jorgensen Biotech Consulting and the Vice President, CMC, Bioanalysis & Clinical Operations at ResoTher Pharma.

Thomas Kjærsgaard Jørgensen began their educational journey in 1976 when they attended the International School of Kenya and obtained their International Baccalaureate in 1985. Thomas Kjærsgaard then went on to attend the Gymnastikhøjskolen i Ollerup from 1985 to 1986. In 1986, they began their studies at Syddansk Universitet - University of Southern Denmark, where they earned an M.Sc. (Cand scient) in Chemistry, Cell Biology, and Biotechnology in 1992. In 1997, they completed a Project Management course at Novo Nordisk. Finally, in 2015, they obtained a Managing Medical Product Innovation (previously SIMI) degree from Copenhagen Business School in Drug Development.